For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Baseline Cross-over Group A--Walkasins ON Then OFF | Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off. After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits. | 0 | None | 0 | 0 | 0 | 0 | View |
| Baseline Cross-over Group B--Walkasins OFF Then ON | Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on. After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits. | 0 | None | 0 | 0 | 0 | 0 | View |
| Single-Arm Long-Term Follow-up (Walkasins ON) | During the baseline visit, participants were randomized to two groups that applied to the first visit only. After the baseline visit, all the participants received Walkasins to wear over the next 52 weeks (single arm). They returned for follow-up visits at weeks 2, 6, 10, 26, and 52. Between weeks 10 and 26 and 26 and 52, they were contacted periodically to remind them of study requirements and to collect follow-up information regarding health changes, adverse events, pain scores, device usage, and device functioning. | 1 | None | 10 | 69 | 24 | 69 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Hospitalizations | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Hospitalizations | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Hospitalizations | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | None | View |
| Hospitalization | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Hospitalization | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Hospitalization | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Hospitalization | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| Hospitalization | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Knee Pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Skin Irritation | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Falls with Minor Injuries | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Hip Pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |